Atricure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $45.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors including Atricure’s strong financial performance in the third quarter of 2025. The company exceeded expectations in revenue, EBITDA, and EPS, and subsequently raised its guidance for 2025. Despite a slight slowdown in revenue growth, Atricure’s gross and operating margins improved significantly, with the latter turning positive for the first time.
Furthermore, Atricure generated substantial cash flow during the quarter, which strengthens its financial position. Matson views the company’s guidance and future estimates as conservative, suggesting that upcoming product launches could further enhance revenue and EBITDA. These positive financial indicators and growth potential underpin Matson’s Buy rating for Atricure’s stock.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRC in relation to earlier this year.